On September 10, Oscar Health, Inc. rose 5.24% in regular trading, trading at $32.69/share, with turnover of $16.41 million. The stock staged a notable rebound following the prior session's sharp decline driven by heavy insider selling.

On September 9, Oscar Health, Inc. had dropped 5.15% after the company disclosed multiple insider transactions, including co-founder and board member Mario Schlosser selling 600,000 shares on August 28 and an additional 31,400 shares on September 3, while executive Richard Scott Blackley also reduced holdings. The concentrated selling triggered market panic, pushing shares as low as $30.44. Today's recovery reflects a technical bounce from oversold levels.

Institutional sentiment has provided additional support. Barclays upgraded the stock to Overweight with a $35 price target, while UBS raised its target to $26 from $20, maintaining a Neutral rating. Fundamentally, the company reported strong Q2 results with revenue of $4.88 billion and EPS of $1.10, both significantly beating consensus estimates. However, management warned that ACA membership churn is expected to accelerate in the second half, leaving questions around growth sustainability.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)